BDX Quote, Financials, Valuation and Earnings

Baxter International has a net margin of 5.84% compared to Becton Dickinson &'s net margin of 4.8%. Becton Dickinson &'s return on equity of 5.86% beat Baxter International's return on equity of -8.24%.

Becton Dickinson & has a consensus price target of $225.25, signalling upside risk potential of 34.88%. On the other hand Baxter International has an analysts' consensus of $38.68 which suggests that it could grow by 27.11%. Given that Becton Dickinson & has higher upside potential than Baxter International, analysts believe Becton Dickinson & is more attractive than Baxter International.

Becton Dickinson & has a beta of 0.312, which suggesting that the stock is 68.788% less volatile than S&P 500. In comparison Baxter International has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.167%.

Becton Dickinson & has a quarterly dividend of $1.04 per share corresponding to a yield of 2.38%. Baxter International offers a yield of 3.02% to investors and pays a quarterly dividend of $0.17 per share. Becton Dickinson & pays 64.52% of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend. Becton Dickinson &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton Dickinson & quarterly revenues are $5.3B, which are larger than Baxter International quarterly revenues of $2.6B. Becton Dickinson &'s net income of $308M is higher than Baxter International's net income of $126M. Notably, Becton Dickinson &'s price-to-earnings ratio is 31.87x while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton Dickinson & is 2.32x versus 1.31x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of 5.84% compared to Becton Dickinson &'s net margin of 14.45%. Becton Dickinson &'s return on equity of 5.86% beat Boston Scientific's return on equity of 9.57%.

Becton Dickinson & has a consensus price target of $225.25, signalling upside risk potential of 34.88%. On the other hand Boston Scientific has an analysts' consensus of $116.12 which suggests that it could grow by 11.4%. Given that Becton Dickinson & has higher upside potential than Boston Scientific, analysts believe Becton Dickinson & is more attractive than Boston Scientific.

Becton Dickinson & has a beta of 0.312, which suggesting that the stock is 68.788% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.

Becton Dickinson & has a quarterly dividend of $1.04 per share corresponding to a yield of 2.38%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Becton Dickinson & pays 64.52% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Becton Dickinson &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton Dickinson & quarterly revenues are $5.3B, which are larger than Boston Scientific quarterly revenues of $4.7B. Becton Dickinson &'s net income of $308M is lower than Boston Scientific's net income of $674M. Notably, Becton Dickinson &'s price-to-earnings ratio is 31.87x while Boston Scientific's PE ratio is 76.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton Dickinson & is 2.32x versus 8.84x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 5.84% compared to Becton Dickinson &'s net margin of 28.26%. Becton Dickinson &'s return on equity of 5.86% beat ResMed's return on equity of 25.76%.

Becton Dickinson & has a consensus price target of $225.25, signalling upside risk potential of 34.88%. On the other hand ResMed has an analysts' consensus of $264.49 which suggests that it could grow by 9.9%. Given that Becton Dickinson & has higher upside potential than ResMed, analysts believe Becton Dickinson & is more attractive than ResMed.

Becton Dickinson & has a beta of 0.312, which suggesting that the stock is 68.788% less volatile than S&P 500. In comparison ResMed has a beta of 0.783, suggesting its less volatile than the S&P 500 by 21.661%.

Becton Dickinson & has a quarterly dividend of $1.04 per share corresponding to a yield of 2.38%. ResMed offers a yield of 0.86% to investors and pays a quarterly dividend of $0.53 per share. Becton Dickinson & pays 64.52% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton Dickinson & quarterly revenues are $5.3B, which are larger than ResMed quarterly revenues of $1.3B. Becton Dickinson &'s net income of $308M is lower than ResMed's net income of $365M. Notably, Becton Dickinson &'s price-to-earnings ratio is 31.87x while ResMed's PE ratio is 27.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton Dickinson & is 2.32x versus 7.07x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 5.84% compared to Becton Dickinson &'s net margin of 11.15%. Becton Dickinson &'s return on equity of 5.86% beat Stryker's return on equity of 14.2%.

Becton Dickinson & has a consensus price target of $225.25, signalling upside risk potential of 34.88%. On the other hand Stryker has an analysts' consensus of $424.26 which suggests that it could grow by 11.25%. Given that Becton Dickinson & has higher upside potential than Stryker, analysts believe Becton Dickinson & is more attractive than Stryker.

Becton Dickinson & has a beta of 0.312, which suggesting that the stock is 68.788% less volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.091%.

Becton Dickinson & has a quarterly dividend of $1.04 per share corresponding to a yield of 2.38%. Stryker offers a yield of 0.86% to investors and pays a quarterly dividend of $0.84 per share. Becton Dickinson & pays 64.52% of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton Dickinson & quarterly revenues are $5.3B, which are smaller than Stryker quarterly revenues of $5.9B. Becton Dickinson &'s net income of $308M is lower than Stryker's net income of $654M. Notably, Becton Dickinson &'s price-to-earnings ratio is 31.87x while Stryker's PE ratio is 51.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton Dickinson & is 2.32x versus 6.34x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.